OBJECTIVES: Paliperidone palmitate long-acting injectable (PP-LAI) is a new once-monthly atypical antipsychotic for the treatment of schizophrenia. This article is to evaluate the efficacy and safety of PP-LAI in the treatment of schizophrenia.  METHODS: Published clinical studies concerning PP-LAI for schizophrenia were searched systemically and assessed by Jadad items. RevMan 5.2 software was used for data analysis and for calculating the combined outcomes of clinical trials and their 95% Confidence Intervals (CI). Furthermore, sensitive analysis and publication bias test were conducted to assess the stability of results from Meta-analysis. RESULTS: